[Primary sino-nasal lymphomas. Apropos of 25 cases].
OBJECTIVE
To report on the epidemiological and therapeutic features of a series of Tunisian patients treated for primitive sinonasal lymphoma.


METHODS
Our retrospective study concerns patients with histologically proven primitive sinonasal lymphoma diagnosed and treated at our institution from 1975 to 1997. Initial work-up included: clinical plus ENT examination, WBC, ESR, LDH, abdominal ultrasonography, bone marrow biopsy and facial CT-scan taken since 1985. All slides are reviewed and reclassified using the Kiel system. Treatment is based on radiotherapy with or without chemotherapy (mainly with the CHOP protocol).


RESULTS
We collected 25 patients (22 males and three females, sex-ratio = 7) with a mean age of 48 years (18 to 78). Mean delay of consultation is 4 months and patients consulted mainly for nasal obstruction (65%), more rarely epistaxis (40%) or rhinorrhea. ENT examination showed a fungating nasal fossa tumor in 20% of cases, predominantly unilateral (80%), associated to cervical nodes in 25% of cases. High-grade lymphomas represented 60% of the cases, and 60% of the patients were stage IE. All stage IEs have been treated by exclusive radiotherapy while more advanced stages received combined chemo- and radiotherapy (eight patients). The five-year actuarial survival rate was 69% for the whole population, with a better prognosis for localized stage and low-grade lymphomas.


CONCLUSIONS
Radiotherapy remains a standard treatment for sinonasal lymphomas, permitting us to cure localized stages. In extended stages (more than IE), combined chemoradiotherapy seems to be a good option, especially in case of bulky tumors as observed for the other nodal and extra-nodal head and neck lymphomas.
Boussen
H
H
Institut Salah-Azaïz, Tunis, Tunisie.
Sethom
A
A
Beddouihech
N
N
Touati
S
S
Gamoudi
A
A
Gritli
S
S
El May
A
A
Ferjaoui
M
M
Benna
F
F
Ladgham
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000402:Airway Obstruction / Q000209:etiology; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004844:Epistaxis / Q000209:etiology; D005260:Female; D006801:Humans; D015993:Life Tables; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009669:Nose Neoplasms / Q000453:epidemiology* / Q000628:therapy; D010255:Paranasal Sinus Neoplasms / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology* / Q000532:radiotherapy; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome; D014416:Tunisia / Q000453:epidemiology